Top

Published in:

01-04-2011 | Review

The treatment of rheumatoid arthritis during pregnancy

Authors: Rosamund Partlett, Euthalia Roussou

Published in: Rheumatology International | Issue 4/2011

Abstract

There are a wide variety of medications available to treat patients with rheumatoid arthritis, many of which are considered unsafe during pregnancy. It is important to tailor a treatment regimen that stabilises the woman’s disease prior to conception, using medications that are safe to continue throughout pregnancy and the post-partum period. Drugs that may be safely used during pregnancy include NSAIDs, corticosteroids, plus several DMARDs, including sulfasalazine and hydroxychloroquine. Drugs recommended to be stopped before pregnancy include methotrexate and leflunomide, plus the biologics: anti-TNF agents, rituximab and abatacept.

Deighton C, Luqmani R (2009) The NICE and BSR guidelines on the management of rheumatoid arthritis (online). Autumn No. 4. Available from http://www.arc.org.uk/arthinfo/medpubs/6544/6544.asp. Accessed 12 Jan 2010

Barrett JH, Brennan P, Fiddler M, Silman AJ (1999) Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheum 42:1219–1227. Available from http://www3.interscience.wiley.com/cgi-bin/fulltext/79503251/PDFSTART. Accessed 12 Jan 2010

Silman AJ, Kay A, Brennan P (1992) Timing of pregnancy in relation to the onset of rheumatoid arthritis (abstract). Arthritis Rheum 35:152–155. Available from http://www.ncbi.nlm.nih.gov/pubmed/1734904?dopt=Abstract. Accessed 12 Jan 2010

Torfs CP, Katz EA, Bateson TF, Lam PK, Curry CJ (1996) Maternal medications and environmental exposures as risk factors for gastroschisis (abstract). Teratology 54:84–92. Available from http://www.ncbi.nlm.nih.gov/pubmed/8948544?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=3. Accessed 12 Jan 2010

Nielsen GL, Sorensen HT, Larsen H, Pedersen L (2001) Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population-based observational study and case-control study. BMJ 322:266–270. Available from http://www.bmj.com/cgi/content/full/322/7281/266?view=long&pmid=11157526. Accessed 12 Jan 2010

Østensen M, Förger F (2009) Management of RA medications in pregnant patients. Nat Rev Rheumatol 5:382–390. Available from http://www.nature.com/nrrheum/journal/v5/n7/pdf/nrrheum.2009.103.pdf. Accessed 12 Jan 2010

Keeling SO, Oswald AE (2009) Pregnancy and rheumatic disease: “by the book” or “by the doc”. Clin Rheumatol 28:1–9. Available from http://www.springerlink.com/content/c7272331544204n3/fulltext.html. Accessed 12 Jan 2010

Chambers CD, Tutuncu ZN, Johnson D, Jones KL (2006) Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data. Arthritis Res Ther 8:225–235. Available from http://arthritis-research.com/content/pdf/ar1977.pdf. Accessed 12 Jan 2010

Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA (2000) Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 343:1608–1614. Available from http://content.nejm.org/cgi/content/abstract/343/22/1608. Accessed 12 Jan 2010

10.

Costedoat-Chalumeau N, Amoura Z, Duhaut P, Huong DLT, Sebbough D, Wechsler B, Vauthier D, Denjoy I, Lupoglazoff J-M, Piette J-C (2003) Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Arthritis Rheum 48:3207–3211PubMedCrossRef

11.

Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L (2007) Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (anti-TNF)-α therapy. Rheumatology 46:695–698PubMedCrossRef

12.

Chambers C, Koren G, Tutuncu ZN, Johnson D, Jones KL (2007) Are new agents used to treat rheumatoid arthritis safe to take during pregnancy? Can Fam Physician 53:409–412PubMed

Title: The treatment of rheumatoid arthritis during pregnancy
Authors: Rosamund Partlett
Euthalia Roussou
Publication date: 01-04-2011
Publisher: Springer-Verlag
Published in: Rheumatology International / Issue 4/2011
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-010-1643-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2011

Biopsychosocial determinants of physical and mental fatigue in patients with spondyloarthropathy

Effective and safe administration of tocilizumab to a patient with rheumatoid arthritis on haemodialysis

Surveillance of systemic autoimmune rheumatic diseases using administrative data

Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis

The effects of PDL-Ig on collagen-induced arthritis

Vitamin D level: is it related to disease activity in inflammatory joint disease?

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials